valproic acid has been researched along with Parkinsonian Disorders in 21 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valproic acid is associated with increased risks of tremor and parkinsonism." | 8.31 | A Case of Long-Term Exposure to Valproic Acid Mimicking Tremor-Dominant Parkinson's Disease. ( Fujimoto, S; Kawai, K; Koide, R; Mashiko, T; Sekiguchi, K; Tanaka, R, 2023) |
| "Valproic acid (VPA) is approved by the Food and Drug Administration (FDA) for the treatment of manic or mixed episodes associated with bipolar disorder." | 7.83 | Reversible Valproic Acid-Induced Parkinsonism and Cognitive Impairment in an Elderly Patient With Bipolar Disorder I. ( Hassamal, S; Reese, K; Testa, C; Waller, S, 2016) |
| "Valproic acid is associated with increased risks of tremor and parkinsonism." | 4.31 | A Case of Long-Term Exposure to Valproic Acid Mimicking Tremor-Dominant Parkinson's Disease. ( Fujimoto, S; Kawai, K; Koide, R; Mashiko, T; Sekiguchi, K; Tanaka, R, 2023) |
| "Valproic acid (VPA) is approved by the Food and Drug Administration (FDA) for the treatment of manic or mixed episodes associated with bipolar disorder." | 3.83 | Reversible Valproic Acid-Induced Parkinsonism and Cognitive Impairment in an Elderly Patient With Bipolar Disorder I. ( Hassamal, S; Reese, K; Testa, C; Waller, S, 2016) |
| "Many cases of valproate-associated parkinsonism have subsequently been published, but uncertainties remain concerning its prevalence, risk factors and prognosis." | 2.53 | Valproate-Associated Parkinsonism: A Critical Review of the Literature. ( Besag, FM; Bhatia, KP; Brugger, F, 2016) |
| "It is well-known that the patients with autosomal recessive juvenile Parkinsonism (ARJP), which is caused by the loss of function mutation in the Parkin gene, often show psychiatric symptoms such as depression, paranoia, psychosis, panic attacks, anorexia nervosa or suicide attempts." | 2.47 | [Pharmacogenetics focused on special phenotypes]. ( Sano, A, 2011) |
| "VPA-induced parkinsonism is a less common but important adverse effect of this drug." | 2.47 | Valproic acid-induced parkinsonism in the elderly: a comprehensive review of the literature. ( Mahmoud, F; Tampi, RR, 2011) |
| "Rest tremor is observed in 11." | 1.62 | Valproate-induced rest tremor and parkinsonism. ( Alonso-Juarez, M; Baizabal-Carvallo, JF, 2021) |
| "The onset of parkinsonism in patients with drug-induced parkinsonism (DIP) exhibits extensive individual variability following exposure to offending drugs." | 1.48 | Early-onset drug-induced parkinsonism after exposure to offenders implies nigrostriatal dopaminergic dysfunction. ( Chung, SJ; Hong, JY; Kim, JS; Lee, PH; Moon, H; Oh, JS; Park, YH; Sohn, YH; Ye, BS; Yoo, HS, 2018) |
| "In order to investigate the mechanisms and therapeutic effects of valproate combined with lithium carbonate on mouse model of Parkinson's disease (PD), male C57BL/6 mice were injected into intraperitoneal with valproate (20 μg/ml) combined with lithium carbonate (10 μg/ml) for 7 days following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) (30 mg/kg) administration, and the effects on motor function were analyzed." | 1.39 | Therapeutic effects of valproate combined with lithium carbonate on MPTP-induced parkinsonism in mice: possible mediation through enhanced autophagy. ( Bai, LM; Chen, XP; Li, XZ; Zhang, H; Zhao, K; Zhou, XP, 2013) |
| "A large cohort of 1528 patients with parkinsonism was analyzed, gathering data on demography, motor and non-motor characteristics, as well as the final etiologic diagnoses based on established criteria." | 1.36 | The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics. ( Munhoz, RP; Teive, HA; Werneck, LC, 2010) |
| "The odds of having parkinsonism were 5 times higher with valproate than with other AEDs." | 1.34 | Movement disorders in patients taking anticonvulsants. ( Asante, AN; Carlen, P; Lang, A; Munhoz, RP; Politzer, N; Wennberg, R; Zadikoff, C, 2007) |
| "Ten cases of reversible parkinsonism associated with VPA in 6 women and 4 men, associated with marked cognitive impairment in six cases, are described." | 1.33 | Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases. ( Andréjak, M; Gras-Champel, V; Masmoudi, K; Masson, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (38.10) | 29.6817 |
| 2010's | 11 (52.38) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Sekiguchi, K | 1 |
| Mashiko, T | 1 |
| Koide, R | 1 |
| Kawai, K | 1 |
| Fujimoto, S | 1 |
| Tanaka, R | 1 |
| Baizabal-Carvallo, JF | 1 |
| Alonso-Juarez, M | 1 |
| Chung, SJ | 1 |
| Yoo, HS | 1 |
| Moon, H | 1 |
| Oh, JS | 1 |
| Kim, JS | 1 |
| Park, YH | 1 |
| Hong, JY | 1 |
| Ye, BS | 1 |
| Sohn, YH | 1 |
| Lee, PH | 1 |
| Harrison, IF | 1 |
| Anis, HK | 1 |
| Dexter, DT | 1 |
| Tada, H | 1 |
| Ogihara, T | 1 |
| Nakamura, T | 1 |
| Sasayama, D | 1 |
| Sugiyama, N | 1 |
| Takahashi, Y | 1 |
| Washizuka, S | 1 |
| Amano, N | 1 |
| Brugger, F | 1 |
| Bhatia, KP | 1 |
| Besag, FM | 1 |
| Hassamal, S | 1 |
| Waller, S | 1 |
| Reese, K | 1 |
| Testa, C | 1 |
| Qian, Y | 1 |
| Zheng, Y | 1 |
| Tiffany-Castiglioni, E | 1 |
| Munhoz, RP | 2 |
| Werneck, LC | 1 |
| Teive, HA | 1 |
| Kidd, SK | 1 |
| Schneider, JS | 1 |
| Sano, A | 1 |
| Mahmoud, F | 1 |
| Tampi, RR | 1 |
| Castro, AA | 1 |
| Ghisoni, K | 1 |
| Latini, A | 1 |
| Quevedo, J | 1 |
| Tasca, CI | 1 |
| Prediger, RD | 1 |
| Li, XZ | 1 |
| Chen, XP | 1 |
| Zhao, K | 1 |
| Bai, LM | 1 |
| Zhang, H | 1 |
| Zhou, XP | 1 |
| Hauben, M | 1 |
| Reich, L | 1 |
| Masmoudi, K | 1 |
| Gras-Champel, V | 1 |
| Masson, H | 1 |
| Andréjak, M | 1 |
| Zadikoff, C | 1 |
| Asante, AN | 1 |
| Politzer, N | 1 |
| Wennberg, R | 1 |
| Carlen, P | 1 |
| Lang, A | 1 |
| Jamora, D | 1 |
| Lim, SH | 1 |
| Pan, A | 1 |
| Tan, L | 1 |
| Tan, EK | 1 |
| Macphee, GJ | 1 |
| Stewart, DA | 1 |
| Sechi, GP | 1 |
| Conti, M | 1 |
| Sau, GF | 1 |
| Cocco, GA | 1 |
| Iijima, M | 1 |
3 reviews available for valproic acid and Parkinsonian Disorders
| Article | Year |
|---|---|
Valproate-Associated Parkinsonism: A Critical Review of the Literature.
Topics: Anticonvulsants; Dopamine; Dopamine Plasma Membrane Transport Proteins; Humans; Migraine Disorders; | 2016 |
[Pharmacogenetics focused on special phenotypes].
Topics: Antipsychotic Agents; Humans; Hyperammonemia; Malignant Hyperthermia; Mutation; Parkinsonian Disorde | 2011 |
Valproic acid-induced parkinsonism in the elderly: a comprehensive review of the literature.
Topics: Age Factors; Aged; Algorithms; Antimanic Agents; Humans; Parkinsonian Disorders; Time Factors; Valpr | 2011 |
18 other studies available for valproic acid and Parkinsonian Disorders
| Article | Year |
|---|---|
A Case of Long-Term Exposure to Valproic Acid Mimicking Tremor-Dominant Parkinson's Disease.
Topics: Aged; Humans; Male; Parkinson Disease; Parkinsonian Disorders; Tomography, Emission-Computed, Single | 2023 |
Valproate-induced rest tremor and parkinsonism.
Topics: Adolescent; Adult; Anticonvulsants; Cohort Studies; Female; Humans; Male; Middle Aged; Parkinsonian | 2021 |
Early-onset drug-induced parkinsonism after exposure to offenders implies nigrostriatal dopaminergic dysfunction.
Topics: Aged; Anticonvulsants; Antiemetics; Antipsychotic Agents; Calcium Channel Blockers; Case-Control Stu | 2018 |
Associated degeneration of ventral tegmental area dopaminergic neurons in the rat nigrostriatal lactacystin model of parkinsonism and their neuroprotection by valproate.
Topics: Acetylcysteine; Animals; Dopaminergic Neurons; Male; Neuroprotective Agents; Parkinsonian Disorders; | 2016 |
A case of severe parkinsonism in an elderly person induced by valproic acid.
Topics: Aged; Amantadine; Anticonvulsants; Brain; Dose-Response Relationship, Drug; Female; Humans; Magnetic | 2017 |
Reversible Valproic Acid-Induced Parkinsonism and Cognitive Impairment in an Elderly Patient With Bipolar Disorder I.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Cognition Disorders; Diagnostic and Statistical Manual of | 2016 |
Valproate reversibly reduces neurite outgrowth by human SY5Y neuroblastoma cells.
Topics: Animals; Antimanic Agents; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cytoskeleton; | 2009 |
The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics.
Topics: Aged; Antipsychotic Agents; Cinnarizine; Cohort Studies; Diagnosis, Differential; Female; Flunarizin | 2010 |
Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Histone Deacetylase Inhibitors; Male; Mice; Mice, Inbred | 2011 |
Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Age Factors; Animals; Anim | 2012 |
Therapeutic effects of valproate combined with lithium carbonate on MPTP-induced parkinsonism in mice: possible mediation through enhanced autophagy.
Topics: Animals; Autophagy; Drug Therapy, Combination; Lithium Carbonate; Male; Mice; Mice, Inbred C57BL; MP | 2013 |
Valproate-induced parkinsonism: use of a newer pharmacovigilance tool to investigate the reporting of an unanticipated adverse event with an "old" drug.
Topics: Anticonvulsants; Databases as Topic; Humans; Parkinsonian Disorders; Valproic Acid | 2005 |
Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases.
Topics: Aged; Anticonvulsants; Cognition Disorders; Epilepsy; Female; Humans; Male; Middle Aged; Parkinsonia | 2006 |
Movement disorders in patients taking anticonvulsants.
Topics: Adult; Aged; Anticonvulsants; Cross-Sectional Studies; Epilepsy; Female; Humans; Male; Middle Aged; | 2007 |
Valproate-induced Parkinsonism in epilepsy patients.
Topics: Adult; Anticonvulsants; Chi-Square Distribution; Epilepsy; Female; Humans; Male; Middle Aged; Parkin | 2007 |
Diagnosis of Parkinsonism in older patients receiving sodium valproate.
Topics: Aged; Depression; Female; Humans; Parkinsonian Disorders; Seizures; Valproic Acid | 2007 |
Valproate-induced parkinsonism, glial cells and Alexander's disease.
Topics: Adult; Alexander Disease; Anticonvulsants; Female; Humans; Magnetic Resonance Imaging; Neuroglia; Pa | 2008 |
Valproate-induced parkinsonism in a demented elderly patient.
Topics: Aged; Aggression; Alzheimer Disease; Humans; Male; Parkinsonian Disorders; Valproic Acid; Violence | 2002 |